Rates and outcomes of parathyroidectomy for secondary hyperparathyroidism in the United States

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 7, 2016, Pages 1260-1267

  Kim, Sun Moon ^a   Long, Jin ^a   Montez Rath, Maria E ^a   Leonard, Mary B ^a   Norton, Jeffrey A ^a   Chertow, Glenn M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic; Health services research; Hospital Mortality; Hospitalization; Humans; Hyperparathyroidism; Kidney Failure; Length of Stay; Nationwide Inpatient Sample; Parathyroidectomy; Secondary

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; END STAGE RENAL DISEASE; FEMALE; HEART FAILURE; HOSPITAL COST; HOSPITAL MORTALITY; HOSPITALIZATION; HUMAN; HYPERTENSION; ICD-9-CM; INFANT; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; OUTCOME ASSESSMENT; PARATHYROIDECTOMY; PERIPHERAL VASCULAR DISEASE; SECONDARY HYPERPARATHYROIDISM; UNITED STATES; COMPLICATION; ECONOMICS; INCIDENCE; MIDDLE AGED; MORTALITY; NEWBORN; PRESCHOOL CHILD; TREATMENT OUTCOME; TRENDS; UTILIZATION; VERY ELDERLY; YOUNG ADULT;

CINACALCET;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CINACALCET HYDROCHLORIDE; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INCIDENCE; INFANT; INFANT, NEWBORN; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MALE; MIDDLE AGED; PARATHYROIDECTOMY; PERIPHERAL VASCULAR DISEASES; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84984841178     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.10370915     Document Type: Article

References (26)

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineralmetabolism,mortality, andmorbidity inmaintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
2. Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC; ARO Investigators: Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 26: 1948-1955, 2011
3. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
4. Kestenbaum B, Seliger SL, Gillen DL, Wasse H, Young B, Sherrard DJ, Weiss NS, Stehman-Breen CO: Parathyroidectomy rates among United States dialysis patients: 1990-1999. Kidney Int 65: 282-288, 2004
5. Foley RN, Li S, Liu J, Gilbertson DT, Chen SC, Collins AJ: The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 16: 210-218, 2005
6. Li S, Chen YW, Peng Y, Foley RN, St Peter WL: Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007. Am J Kidney Dis 57: 602-611, 2011
7. St Peter WL, Li Q, Liu J, Persky M, Nieman K, Arko C, Block GA: Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 4: 354-360, 2009
8. Yusuf AA, Howell BL, Powers CA, St Peter WL: Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D. Am J Kidney Dis 64: 770-780, 2014
9. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68: 1793-1800, 2005
10. El-Shafey EM, Alsahow AE, Alsaran K, Sabry AA, Atia M: Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial 15: 547-555, 2011
11. Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS; EVOLVE Trial Investigators: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. NEngl J Med 367:2482-2494, 2012
12. United States Renal Data System: 2014 Annual Data Report: An Overview of the Epidemiology of Kidney Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2014
13. Malberti F, Marcelli D, Conte F, Limido A, Spotti D, Locatelli F:Parathyroidectomy in patients on renal replacement therapy: An epidemiologic study. J Am Soc Nephrol 12: 1242-1248, 2001
14. Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project: Introduction to the HCUP Nationwide Inpatient Sample (NIS), 2011. Available at: https://www.hcupus. ahrq.gov/db/nation/nis/NIS_Introduction_2011.jsp. Accessed July 10, 2015
15. Healthcare Cost and Utilization Project (HCUP): Cost-to-Charge Ratio Files. Available at: http://www.hcup-us.ahrq.gov/db/state/ costtocharge.jsp. Accessed September 23, 2015
16. Lafrance JP, Cardinal H, Leblanc M, Madore F, Pichette V, Roy L, Le Lorier J: Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends. BMC Nephrol 14: 100, 2013
17. Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, Andreucci VE, Fukagawa M, Frimat L, Mendelssohn DC, Port FK, Pisoni RL, Robinson BM: Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: The DOPPS study. Clin J Am Soc Nephrol 10: 98-109, 2015
18. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1-S201, 2003
19. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and BoneDisorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009
20. Kilpatrick RD, Newsome BB, Zaun D, Liu J, Solid CA, Nieman K, St Peter WL: Evaluating real-world use of cinacalcet and biochemical response to therapy in US hemodialysis patients. Am J Nephrol 37: 389-398, 2013
21. Ureña P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, Leavey S, Rix M, Os I, Saha H, Ryba M, Bencova V, Baños A, Zani V, Fouque D: Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice-the ECHO observational study. Nephrol Dial Transplant 24: 2852-2859, 2009
22. Martin KJ, Pickthorn K, Huang S, Block GA, Vick A, Mount PF, Power DA, Bell G: AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a singledose study in hemodialysis patients. Kidney Int 85: 191-197, 2014
23. Bell G, Huang S, Martin KJ, Block GA: A randomized, doubleblind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin 31: 943-952, 2015
24. Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, Sherrard DJ, Stehman-Breen C: Survival following parathyroidectomyamongUnited States dialysis patients. Kidney Int 66: 2010-2016, 2004
25. Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, Block GA, Collins AJ: Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol 10: 90-97, 2015
26. Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Fukagawa M: Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 88: 350-359, 2015